Track ChromaDex Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

ChromaDex Corporation CDXC · Stock Open ChromaDex Corporation in new tab

7.87 USD
P/E
382.00
EPS
0.02
P/B
16.94
ROE
4.82
Beta
1.88
Target Price
7.96 USD
Loading chart...
Key Metrics
P/E382.00
EPS0.02
Book Value0.45
Price to Book16.94
Debt/Equity8.42
% Insiders35.398%
Growth
Revenue Growth0.31%
Estimates
Forward P/E57.66
Forward EPS0.12
Target Mean Price7.96

DCF valuation

Model fair value for ChromaDex Corporation (CDXC)
Result
Sign in to run the valuation for CDXC.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 7.96 USD (low 5.00, high 12.00)
Low 5.00
Mean 7.96
High 12.00
Price 7.87
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

ChromaDex Corporation Logo ChromaDex Corporation Analysis (CDXC)

United States Health Care Official Website Stock

Is ChromaDex Corporation a good investment? ChromaDex Corporation (CDXC) is currently trading at 7.87 USD. Market analysts have a consensus price target of 7.96 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 382.00. This high multiple suggests investors have priced in significant future growth expectations.

Investor FAQ

Does ChromaDex Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is ChromaDex Corporation?

ChromaDex Corporation is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Exchange Ticker
NAGE
NMS (United States) CDXC
FRA (Germany) OCD1.F
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 13, 2016 1:3
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion